The identification of specific genetic mutations associated with certain types of malformations and lesions, such as PIK3CA mutations in lymphatic malformations and GNA14 mutations in Kaposiform Haemangioendothelioma, has opened doors for targeted therapies using pathway inhibitors [2,9]. The gene discussed is PIK3CA; the disease is lymphatic malformation.